Job offer: Three Independent Junior Research Group Leaders in Single Cell Approaches for Personalized Medicine

The Berlin Institute of Health (BIH) is a biomedical research institution focusing on translational research and precision medicine. BIH uses a systems medicine approach to develop innovative options for prediction, prevention and advanced therapies for progressive diseases in order to improve patients’ health and quality of life. To realize its innovative plans in translational research, BIH builds on the strengths and expertise of its founding institutions Charité – Universitätsmedizin Berlin and Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC). (https://www.bihealth.org/en).

The Berlin Institute for Medical Systems Biology (BIMSB), located in the center of Berlin, is a strategic expansion of the MDC to establish major expertise in the field of Systems and Single cell biology. (https://www.mdc-berlin.de/bimsb)

In order to strengthen translational research within the dynamic field of single cell approaches and to give promising researchers the possibility of independent scientific work, BIH and MDC/BIMSB jointly invite applications for the following positions:

Three independent junior group leaders in single cell approaches for personalized medicine

with possible tenure as full professor

The 3 independent junior research groups are to be a central element within the new Clinical Research Focus on “Single cell Approaches for Personalized Medicine” jointly established by BIH, MDC and Charité bridging basic and clinical research. Each junior research group will closely collaborate with a clinical department at the Charité on a specific disease, disease area or disease mechanism. Possible research areas include, but are not limited to cancer, inflammation, re-/degeneration, neurodegenerative, cardiovascular or rare diseases.

As leaders of the junior research group it is expected that successful candidates will conduct independent research at the MDC/BIMSB in close collaboration with partnering clinical units at the Charité and are prepared to foster technological development for clinical translation.

Your profile:

We invite applications from outstanding scientists with demonstrated expertise in single cell molecular profiling, cell lineage tracing, and/or imaging. We are specifically looking for candidates who investigate mechanisms of human disease progression at the single cell level or who develop novel methods for early diagnosis and effective interception of disease.

  • Applicants must hold a doctorate (Ph.D. and/or M.D.) in the life sciences or related areas
  • Applicants must have an excellent track record demonstrating highly successful research and translational relevance
  • Applicants should have demonstrable working experience in an interdisciplinary research environment
  • It is desirable that applicants have got first experiences in clinical research or are highly motivated for it
  • Applicants are expected to have excellent communication skills and leadership potential

BIH, Charité and MDC are committed to excellence through diversity and in particular to increasing the proportion of women among the scientific staff. Applications from women are explicitly encouraged. Equally qualified applicants with disabilities will be given preference.

What we offer?

BIH and MDC offer an attractive start-up package including the group leader’s position (salary according to the German public salary scheme TVöD Bund/Ost), start-up investment, one postdoc, one PhD student, one technician, as well as fixed annual consumables and additional opportunities to recruit students from the MDC’s PhD or Fellowship Programs. Laboratories of the successful candidates are equipped with state-of-the-art facilities and are located in the new BIMSB building, within walking distance from the Charité campus in Berlin Mitte.

The appointment of successful candidates is handled according to the BIH tenure option scheme:

  • Initial appointment is for 5 years with a possible extension for additional 2 years depending on a positive evaluation of the research group in the 4th year
  • Based on a scientific evaluation in the 6th year, BIH and its partners will decide on a tenured appointment of the candidate for a full professorship (Salary group: W3 BBesG).

How to apply?

Applications for both positions will be accepted via our online application portal at https://portal.bihealth.de/portal/SitePages/Portal.aspx. 

Before starting your application, you first have to create your account for the BIH application portal by registering with your name and a valid email address. Once you are registered and signed in, you click on "Start new application" and select the appropriate call below: “Application for BIH-BIMSB_ Independent Junior_Research_Group Leader”. To continue working on a previously saved application, please click "My applications" and choose the application you want to continue working on under "My draft applications". 

For your application we kindly ask to provide and upload the following documents:

  • Curriculum vitae with details on your occupational career and academic achievements with lists of publications, academic teaching and obtained third party funding for research projects
  • Concept for research program outlining also the specific focus on a disease area or disease mechanism in fields like neuroscience, cancer, inflammation or re/degeneration (max. 5 pages)
  • Copies of your certificates relating to your qualifications and achievements

Application deadline: Please upload your full application in English by 26. November 2019.


Selection procedure and Match-Making with Charité Clinical Departments

Based on the received applications a selection committee will shortlist applications and invite suited candidates for a symposium. For candidates who have convinced with regards to scientific excellence and innovative potential of the proposed research program, a matching process with Charité clinical departments will be initiated. Successful candidates will present their research programs that combine innovative cell technologies with a disease application that is supported by the interest of a strong clinical partner at Charité and thereby convincingly drives translation.